Skip to main content

Table 5 Post-operative primary and secondary outcomes

From: Is there a renoprotective value to leukodepletion during heart valve surgery? A randomized controlled trial (ROLO)

   Randomized to leukodepletion filter
(n = 32)
Randomized to standard filter
(n = 31)
Overall (n = 63)
n % n % n % (95% CI)
PRIMARY OUTCOME:
Any AKI At any time 14/32 44% 7/31 23% 21/63 33% (0.22, 0.46)
Prior to discharge 14/29 48% 6/25 24% 20/54 37%  
Between discharge and 6 weeks ~ 0/26 0% 1/24 4% 1/50 2%  
 Highest AKI stage Stage 1 9/14 64% 4/6 67% 13/20 65%  
Stage 2 4/14 29% 1/6 17% 5/20 25%  
Stage 3 1/14 7% 1/6 17% 2/20 10%  
 First instance of AKI Day 1 9/14 64% 2/6 33% 11/20 55%  
Day 2 4/14 29% 3/6 50% 7/20 35%  
Day 3 to discharge 1/14 7% 1/6 17% 2/20 10%  
 Maximum AKI stage Day 1 6/14 43% 0/6 0% 6/20 30%  
Day 2 7/14 50% 5/6 83% 12/20 60%  
Day 3 to discharge 1/14 7% 1/6 17% 2/20 10%  
SECONDARY OUTCOMES:
 Need for haemodialysis 1/32 3% 0/31 0% 1/63 2% (0.0,0.1)
 In hospital mortality 2/32 6% 0/31 0% 2/63 3% (0.0,0.1)
 Infection complications 5/32 16% 4/31 13% 9/63 14% (0.1,0.3)
Length of post-operative stay Median (IQR) days 7.7 (5.8, 13.9) 8.8 (5.9, 11.7) 7.9 (5.9, 12.0)  
CICU length of stay Median (IQR) days 47.3 (24.8, 100.0) 48.5 (26.6, 92.8) 48.5 (25.0, 98.3)  
Ward length of stay Median (IQR) days 120.8 (94.0, 168.8) 141.5 (92.0, 188.4) 121.3 (93.5, 187.0)